TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9621317
Drug: Ultraviolet laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraviolet laser therapy (UVLT)
Study: 1890604
Drug: AL 721
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL 721 (20, 30, 40, or 50 g orally twice daily for 8 weeks)
Study: 367411
Drug: Cyclizine 100
Normalized name: cyclizine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine 100 mg
Study: 17042842
Drug: Cyclizine 50
Normalized name: cyclizine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine 50 mg
Study: 11497156
Drug: High-volume haemofiltration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume haemofiltration (HVHF; 6 l/h)
Study: 11497156
Drug: Standard continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard continuous veno-venous haemofiltration (CVVH; 1 l/h)
Study: 11497156
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (HVHF and CVVH)
Study: 8221579
Drug: Daunorubicin infusion
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin infusion
Study: 24915899
Drug: FOLFIRI+PB (panitumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI+PB (panitumumab 3 mg/kg and bevacizumab 3 mg/kg plus FOLFIRI every other week)
Study: 12689743
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Doxazosin and Finasteride
Study: 10476945
Drug: Sublingual human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual human interferon-alpha (IFN-alpha) 15 IU
Study: 10476945
Drug: Sublingual human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual human interferon-alpha (IFN-alpha) 150 IU
Study: 12057718
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg twice daily)
Study: 8701785
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (100 mg on days 5-14 of the menstrual cycle)
Study: 6418100
Drug: Quinidine (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (700 to 1100 mg/day)
Study: 6168848
Drug: Disopyramide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (600 mg/day)
Study: 29753661
Drug: Protocol 1
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 1 (P1) with 120 kVp, 180mAs, and 100mL of contrast agent with filtered back‐projection (FBP)
Study: 29753661
Drug: Protocol 2
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 2 (P2) with 80 kVp, 140mAs and 75mL of contrast agent with hybrid iterative reconstruction
Study: 29753661
Drug: Protocol 3
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 3 (P3) with 80 kVp, 140mAs and 75mL of contrast agent with iterative model reconstruction (IMR)
Study: 11996209
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A
Study: 11996209
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B
Study: 7714743
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C
Study: 15998607
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual control group without access to the ODIN website (n = 100)
Study: 8597466
Drug: DHEA 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 300 mg, orally three times daily for 14 days
Study: 8597466
Drug: Placebo capsule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, orally three times daily for 14 days
Study: 2548905
Drug: 0.25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 micrograms alpha‐calcoid given orally twice daily (n = 9)
Study: 23769863
Drug: Inhaled extra-fine
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled extra-fine beclomethasone/formoterol (I‐EF‐BDP/F)
Study: 17175304
Drug: Sirolimus-based calcineurin
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus-based calcineurin inhibitor (CNI)-free regimen (sirolimus 5 mg daily starting postoperative day 3, mycophenolate mofetil 1 gm twice a day, methylprednisolone 500 mg intraoperatively, prednisone 30 mg daily tapered to 10 mg daily at 3 months)
Study: 17175304
Drug: Tacrolimus-based steroid-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus-based steroid-free regimen (tacrolimus 0.075 mg/kg twice a day, mycophenolate mofetil 1 g twice a day, methylprednisolone 500 mg, 250 mg, and 125 mg from days 0 to 2, then no further steroids)
Study: 27929346
Drug: d-amphetamine 0
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 0 mg (placebo)
Study: 7285484
Drug: d-amphetamine 5
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 5 mg
Study: 21894485
Drug: d-amphetamine 20
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 20 mg
Study: 12927652
Drug: d-amphetamine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (all doses)
Study: 10620000
Drug: Nitroglycerin-releasing 'active'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin-releasing 'active' patches (approx. 0.4 mg hour‐1 nitroglycerin)
Study: 8620093
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal therapy (Zemaphyte) for 8 weeks
Study: 8620093
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal therapy (Zemaphyte)
Study: 3919754
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream containing 4% sodium cromoglycate (SCG)
Study: 24946630
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group used triamcinolone acetonide cream externally and locally, twice a day for 15 days.
Study: 24946630
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups underwent treatment for 3 sessions, with hemorheology tests and radioimmunoassays for IL-2, IL-6, IL-10, and TNF-alpha levels.
Study: 18041396
Drug: Noninvasive Mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive Mechanical Ventilation (MV) in patients with Cst > 0.025 L/cm H2O
Study: 18041396
Drug: Invasive Mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive Mechanical Ventilation (MV) in patients with Cst > 0.025 L/cm H2O
Study: 18041396
Drug: Noninvasive Mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive Mechanical Ventilation (MV) in patients with Cst <= 0.025 L/cm H2O
Study: 18041396
Drug: Invasive Mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive Mechanical Ventilation (MV) in patients with Cst <= 0.025 L/cm H2O
Study: 16116046
Drug: Valsartan/Hydrochlorothiazide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Hydrochlorothiazide (160 mg/12.5 mg)
Study: 8584772
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with fentanyl (10 micrograms/kg initial dose, followed by 5 micrograms/kg/h infusion)
Study: 2236433
Drug: beta‐adrenoceptor blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐adrenoceptor blockade (100 mg of atenolol)
Study: 486932
Drug: High-nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-nicotine cigarettes (1.84 mg standard yield)
Study: 486932
Drug: Low-nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-nicotine cigarettes (0.6 mg standard yield)
Study: 486932
Drug: Medium-nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-nicotine cigarettes (1.4 mg standard yield)
Study: 30497684
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 750-1000 mg/m2 daily
Study: 30497684
Drug: Levamisole 2-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 2-2.5 mg/kg on alternate days
Study: 27986549
Drug: Clinical treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical treatment (Control group)
Study: 25504994
Drug: Nintedanib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 50 mg twice daily for 14 days
Study: 25504994
Drug: Nintedanib 100
Normalized name: nintedanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 100 mg twice daily for 14 days
Study: 25504994
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg twice daily for 28 days
Study: 25504994
Drug: Nintedanib added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib added to ongoing pirfenidone therapy
Study: 20135132
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg estradiol vaginal tablets (group I)
Study: 20135132
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyaluronic acid sodium salt vaginal tablets (group II)
Study: 16734312
Drug: Prompt‐L‐Pop with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt‐L‐Pop with Dyract Seal
Study: 16734312
Drug: Prompt‐L‐Pop with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt‐L‐Pop with Concise
Study: 16734312
Drug: Prompt‐L‐Pop with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt‐L‐Pop with Visio‐Seal
Study: 16734312
Drug: Prompt‐L‐Pop with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt‐L‐Pop with Helioseal
Study: 15119985
Drug: Quality assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality assessment of meta-analyses of RCTs of pharmacotherapy for MDD
Study: 11402910
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg for 4 weeks
Study: 11402910
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 16 mg for 4 weeks
Study: 21050239
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 treatment
Study: 29522710
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d vitamin C as a twice daily bolus infusion
Study: 29522710
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d vitamin C as continuous infusion
Study: 29522710
Drug: 10 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/d vitamin C as a twice daily bolus infusion
Study: 29522710
Drug: 10 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/d vitamin C as continuous infusion
Study: 29522710
Drug: 10 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/d vitamin C (all regimens)
Study: 29522710
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d vitamin C (all regimens)
Study: 29522710
Drug: Post-discontinuation of
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discontinuation of vitamin C
Study: 25969567
Drug: Lifestyle changes
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle changes and guideline-based treatment according to ADA recommendations
Study: 22585884
Drug: Pedometer step‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer step‐based Green Prescription
Study: 22585884
Drug: Standard Green
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Green Prescription
Study: 17645076
Drug: Intravenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous laser radiation of blood (ILRB)
Study: 17645076
Drug: Antioxidant drug
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant drug cytoflavin
Study: 12440352
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin supplementation (vitamin E 600 mg/day, vitamin C 250 mg/day, betacarotene 20 mg/day)
Study: 9019387
Drug: Etidocaine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidocaine (15 mg/ml)
Study: 9019387
Drug: Bupivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (5 mg/ml) + Lidocaine (10 mg/ml)
Study: 29169838
Drug: Lidocaine (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (260 mg of 2% lidocaine subcutaneously and intratesticularly 5 minutes prior to castration)
Study: 29169838
Drug: Meloxicam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (0.5 mg kg−1 of meloxicam subcutaneously 30 minutes prior to castration)
Study: 29169838
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative analgesia administered)
Study: 26512601
Drug: Peginterferon/ribavirin (P‐R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon/ribavirin (P‐R) treatment
Study: 15476908
Drug: Tobramycin 3
Normalized name: tobramycin 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 3 mg/mL plus dexamethasone 1 mg/mL (TD)
Study: 15476908
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg/mL plus neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 6000 IU/mL (DNP)
Study: 15476908
Drug: Neomycin sulfate
Normalized name: Neomycin Sulfate
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 7500 IU/mL plus gramicidin 20 microg/mL (NPG)
Study: 11902023
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy group
Study: 9493884
Drug: Daily inner
Normalized name: isosulfan blue inner salt
DrugBank: Isosulfan blue (DB09136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily inner cannula changes
Study: 8067499
Drug: Propranolol, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 60 mg or less, administered daily between 5:30 and 6:00 a.m.
Study: 3052917
Drug: GIK cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK cardioplegic solution with calcium and PGI2 analogue (OP-41483, 300 micrograms/l)
Study: 3052917
Drug: GIK cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK cardioplegic solution with calcium (1.2 mM)
Study: 3052917
Drug: Basic GIK
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic GIK cardioplegic solution alone (no added calcium)
Study: 31597806
Drug: Curcumin gel
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin gel applied post-scaling and root planing (SRP)
Study: 31597806
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no curcumin gel)
Study: 28283490
Drug: GOPC medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOPC medical treatment orders
Study: 24625625
Drug: Tanezumab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab monotherapy (5 or 10 mg)
Study: 24625625
Drug: Tanezumab +
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab + NSAIDs (naproxen 500 mg twice daily or celecoxib 100 mg twice daily)
Study: 24625625
Drug: Tanezumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab (5 or 10 mg)
Study: 21982649
Drug: Canakinumab (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (50, 150, or 300 mg every 3 months, administered subcutaneously)
Study: 19238654
Drug: gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil 1200 mg
Study: 26539650
Drug: atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 40 mg
Study: 10882574
Drug: Enhanced‐potency inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced‐potency inactivated poliovirus vaccine (E‐IPV) followed by monovalent oral poliovirus vaccine (OPV, type 3 Sabin)
Study: 8807623
Drug: Disodium monofluorophosphate
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium monofluorophosphate (MFP) 13.2 mg/day + calcium (1,000 mg/day) + calcifediol (50 micrograms/day)
Study: 8807623
Drug: Calcium (1,000
Normalized name: calcium carbonate 390 mg calcium (1,000 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1,000 mg/day) + calcifediol (50 micrograms/day)
Study: 6586292
Drug: Interferon-alpha A
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha A (1 ng/ml)
Study: 6586292
Drug: Interferon-alpha D
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha D (1 ng/ml)
Study: 27117223
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 2000 ml/h
Study: 27117223
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 1000 ml/h
Study: 27117223
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 500 ml/h
Study: 20061913
Drug: Steroid avoidance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid avoidance or withdrawal (SAW)
Study: 11085964
Drug: Nitroglycerin (sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (sublingual administration)
Study: 11973410
Drug: NG‐monomethyl‐l‐arginine (infusion)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐l‐arginine (infusion)
Study: 10962387
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy + ranitidine (n = 180)
Study: 10962387
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy alone (n = 163)
Study: 10962387
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy + ranitidine
Study: 10962387
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy alone
Study: 12361129
Drug: 2% erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% erythromycin gel
Study: 1600584
Drug: 0.6 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 micrograms yeast-derived hepatitis B vaccine
Study: 1600584
Drug: 1.25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 micrograms yeast-derived hepatitis B vaccine
Study: 1600584
Drug: 2.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 micrograms yeast-derived hepatitis B vaccine
Study: 1600584
Drug: 5.0 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 micrograms yeast-derived hepatitis B vaccine
Study: 1600584
Drug: All dosages
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosages of yeast-derived hepatitis B vaccine
Study: 6230611
Drug: Electronic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electronic infusion controller (IVAC 230)
Study: 6230611
Drug: Standard infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard infusion method (control group)
Study: 29526749
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of Oxytocin
Study: 12768912
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of eptifibatide
Study: 10597554
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (3 micrograms.kg‐1.min‐1) (Group A)
Study: 10597554
Drug: Dextrose infusion
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose infusion (control) (Group B)
Study: 8605791
Drug: 11 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 ppm inhaled nitric oxide
Study: 8605791
Drug: 60 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ppm inhaled nitric oxide
Study: 11435053
Drug: 40 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ppm inhaled nitric oxide
Study: 9367476
Drug: 10 ppm
Normalized name: Glycerin 1.0 g in 25 mL TOPICAL CREAM [EGF Crystal 10 ppm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ppm inhaled nitric oxide
Study: 29766634
Drug: Comparators (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparators (placebo, sitagliptin, exenatide extended release, insulin glargine)
Study: 26251112
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy (30-35 minutes, once a week for 12 weeks)
Study: 26251112
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no reminiscence therapy)
Study: 24025983
Drug: Mericitabine 500
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mericitabine 500 mg